Management of chronic hepatitis C in French departments of internal medicine and infectious diseases

This prospective, multicentre study was conducted during 2–30 April 2001 in the internal medicine/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic eval...

Full description

Saved in:
Bibliographic Details
Published in:Epidemiology and infection 2005-04, Vol.133 (2), p.305-314
Main Authors: CACOUB, P., GODEREL, I., MORLAT, P., SENE, D., MYERS, R. P., ALRIC, L., LOUSTAUD-RATTI, V., MELIN, P., LIMAL, N., OUZAN, D., PERRONNE, C., CARRAT, F.
Format: Article
Language:English
Subjects:
Adult
Antigens
Antiviral Agents - therapeutic use
Antivirals
Biochemistry
Biological and medical sciences
Biopsies
Biopsy
Chronic hepatitis
Cirrhosis
Departments
Drug use
Epidemiology
Female
France
Fundamental and applied biological sciences. Psychology
Gastroenterology
Genotype
Genotype & phenotype
Hepacivirus
Hepatitis B
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - diagnosis
Hepatitis B, Chronic - drug therapy
Hepatitis C
Hepatology
HIV
HIV Infections - drug therapy
Hospitals, University - statistics & numerical data
Human viral diseases
Humans
Infections
Infectious diseases
Interferons
Internal medicine
Internal Medicine - statistics & numerical data
Liver
Liver - pathology
Liver cancer
Male
Medical sciences
Medicine
Microbiology
Middle Aged
Patients
Physicians
Prospective Studies
RNA
RNA, Viral - analysis
Substance Abuse, Intravenous
Viral diseases
Viral hepatitis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c588t-42231e80b704bc5bb642b281ac32f09a7f023241a0dcd99aace7b55632a84df83
cites
container_end_page 314
container_issue 2
container_start_page 305
container_title Epidemiology and infection
container_volume 133
creator CACOUB, P.
GODEREL, I.
MORLAT, P.
SENE, D.
MYERS, R. P.
ALRIC, L.
LOUSTAUD-RATTI, V.
MELIN, P.
LIMAL, N.
OUZAN, D.
PERRONNE, C.
CARRAT, F.
description This prospective, multicentre study was conducted during 2–30 April 2001 in the internal medicine/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic evaluation of HCV infection performed (HCV RNA, genotype, liver biopsy); determine the proportion and characteristics of patients receiving antiviral treatment; and determine if any changes in these parameters had occurred between 1995 and 2001. Patients whom had a complete pre-therapeutic evaluation (39%, 709/1834) and received antiviral treatment (38%, 690/1830) were more likely to have abnormal liver biochemistry, cirrhosis and cryoglobulinaemia (P
doi_str_mv 10.1017/S0950268804003486
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2870250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0950268804003486</cupid><jstor_id>3865492</jstor_id><sourcerecordid>3865492</sourcerecordid><originalsourceid>FETCH-LOGICAL-c588t-42231e80b704bc5bb642b281ac32f09a7f023241a0dcd99aace7b55632a84df83</originalsourceid><addsrcrecordid>eNp1kV2rEzEQhoMonlr9AYLIIujd6iSbr70RpHjOESviUfEyzGazbeo2W5Ot6L83S0vrB14F8jwzzDtDyEMKzylQ9eIj1AKY1Bo4QMW1vEVmlMu65Bzq22Q24XLiF-ReShsAqJlWd8kFFZpKKuSMtO8w4MptXRiLoSvsOg7B22Ltdjj60adiUfhQXEYX7Lpo828cJzdNsg-jiwH7Yutab31wBYY2_3bOjn7Yp6L1yWFy6T6502Gf3IPjOyefL19_WlyXy_dXbxavlqUVWo8lZ6yiTkOjgDdWNI3krGGaoq1YBzWqDljFOEVobVvXiNapRghZMdS87XQ1Jy8PfXf7Js9k86ARe7OLfovxpxnQmz9J8GuzGr6bvBVgAnKDZ8cGcfi2d2k0W5-s63sMLgcyVEkBWlVZfPKXuBn20y6SYSC4EgomiR4kG4eUoutOk1Aw0wHNPwfMNY9_j3CuOF4sC0-PAiaLfRcxWJ_OnpRM0bzIOXl08DZpHOKJV1oKXk-4PGCfRvfjhDF-NVJVShh59cHUb_nyC7u5MdfZr45ZcNtE367cOfH_0_wCGCLLvg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205475703</pqid></control><display><type>article</type><title>Management of chronic hepatitis C in French departments of internal medicine and infectious diseases</title><source>Cambridge Journals Online</source><source>JSTOR Archival Journals and Primary Sources Collection</source><source>PubMed Central</source><creator>CACOUB, P. ; GODEREL, I. ; MORLAT, P. ; SENE, D. ; MYERS, R. P. ; ALRIC, L. ; LOUSTAUD-RATTI, V. ; MELIN, P. ; LIMAL, N. ; OUZAN, D. ; PERRONNE, C. ; CARRAT, F.</creator><creatorcontrib>CACOUB, P. ; GODEREL, I. ; MORLAT, P. ; SENE, D. ; MYERS, R. P. ; ALRIC, L. ; LOUSTAUD-RATTI, V. ; MELIN, P. ; LIMAL, N. ; OUZAN, D. ; PERRONNE, C. ; CARRAT, F. ; GERMIVIC Group</creatorcontrib><description><![CDATA[This prospective, multicentre study was conducted during 2–30 April 2001 in the internal medicine/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic evaluation of HCV infection performed (HCV RNA, genotype, liver biopsy); determine the proportion and characteristics of patients receiving antiviral treatment; and determine if any changes in these parameters had occurred between 1995 and 2001. Patients whom had a complete pre-therapeutic evaluation (39%, 709/1834) and received antiviral treatment (38%, 690/1830) were more likely to have abnormal liver biochemistry, cirrhosis and cryoglobulinaemia (P<0·001). Injecting drug users and HIV-co-infected patients were less likely to have a complete pre-therapeutic evaluation or receive antiviral treatment (P<0·001). A complete pre-therapeutic evaluation was more often performed in 2001 than in 1995 (39% vs. 6%, P<0·001), including qualitative HCV RNA testing (91% vs. 68%, P<0·001), genotyping (59% vs. 7%, P<0·001) and a liver biopsy (60% vs. 29%, P<0·001). The frequency of anti-HCV treatment approximately doubled between 1995 and 2001 (20% vs. 38%, P<0·001). Although adherence to consensus recommendations regarding pre-therapeutic evaluation is not ideal, a substantial improvement has occurred since 1995. Nevertheless, means of increasing the availability of antiviral therapies, particularly for patients with HIV co-infection or injecting drug use, require further study.]]></description><identifier>ISSN: 0950-2688</identifier><identifier>EISSN: 1469-4409</identifier><identifier>DOI: 10.1017/S0950268804003486</identifier><identifier>PMID: 15816156</identifier><identifier>CODEN: EPINEU</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Adult ; Antigens ; Antiviral Agents - therapeutic use ; Antivirals ; Biochemistry ; Biological and medical sciences ; Biopsies ; Biopsy ; Chronic hepatitis ; Cirrhosis ; Departments ; Drug use ; Epidemiology ; Female ; France ; Fundamental and applied biological sciences. Psychology ; Gastroenterology ; Genotype ; Genotype &amp; phenotype ; Hepacivirus ; Hepatitis B ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - diagnosis ; Hepatitis B, Chronic - drug therapy ; Hepatitis C ; Hepatology ; HIV ; HIV Infections - drug therapy ; Hospitals, University - statistics &amp; numerical data ; Human viral diseases ; Humans ; Infections ; Infectious diseases ; Interferons ; Internal medicine ; Internal Medicine - statistics &amp; numerical data ; Liver ; Liver - pathology ; Liver cancer ; Male ; Medical sciences ; Medicine ; Microbiology ; Middle Aged ; Patients ; Physicians ; Prospective Studies ; RNA ; RNA, Viral - analysis ; Substance Abuse, Intravenous ; Viral diseases ; Viral hepatitis</subject><ispartof>Epidemiology and infection, 2005-04, Vol.133 (2), p.305-314</ispartof><rights>2005 Cambridge University Press</rights><rights>Copyright 2005 Cambridge University Press</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c588t-42231e80b704bc5bb642b281ac32f09a7f023241a0dcd99aace7b55632a84df83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/3865492$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0950268804003486/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,58238,58471,72960</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16627122$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15816156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CACOUB, P.</creatorcontrib><creatorcontrib>GODEREL, I.</creatorcontrib><creatorcontrib>MORLAT, P.</creatorcontrib><creatorcontrib>SENE, D.</creatorcontrib><creatorcontrib>MYERS, R. P.</creatorcontrib><creatorcontrib>ALRIC, L.</creatorcontrib><creatorcontrib>LOUSTAUD-RATTI, V.</creatorcontrib><creatorcontrib>MELIN, P.</creatorcontrib><creatorcontrib>LIMAL, N.</creatorcontrib><creatorcontrib>OUZAN, D.</creatorcontrib><creatorcontrib>PERRONNE, C.</creatorcontrib><creatorcontrib>CARRAT, F.</creatorcontrib><creatorcontrib>GERMIVIC Group</creatorcontrib><title>Management of chronic hepatitis C in French departments of internal medicine and infectious diseases</title><title>Epidemiology and infection</title><addtitle>Epidemiol. Infect</addtitle><description><![CDATA[This prospective, multicentre study was conducted during 2–30 April 2001 in the internal medicine/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic evaluation of HCV infection performed (HCV RNA, genotype, liver biopsy); determine the proportion and characteristics of patients receiving antiviral treatment; and determine if any changes in these parameters had occurred between 1995 and 2001. Patients whom had a complete pre-therapeutic evaluation (39%, 709/1834) and received antiviral treatment (38%, 690/1830) were more likely to have abnormal liver biochemistry, cirrhosis and cryoglobulinaemia (P<0·001). Injecting drug users and HIV-co-infected patients were less likely to have a complete pre-therapeutic evaluation or receive antiviral treatment (P<0·001). A complete pre-therapeutic evaluation was more often performed in 2001 than in 1995 (39% vs. 6%, P<0·001), including qualitative HCV RNA testing (91% vs. 68%, P<0·001), genotyping (59% vs. 7%, P<0·001) and a liver biopsy (60% vs. 29%, P<0·001). The frequency of anti-HCV treatment approximately doubled between 1995 and 2001 (20% vs. 38%, P<0·001). Although adherence to consensus recommendations regarding pre-therapeutic evaluation is not ideal, a substantial improvement has occurred since 1995. Nevertheless, means of increasing the availability of antiviral therapies, particularly for patients with HIV co-infection or injecting drug use, require further study.]]></description><subject>Adult</subject><subject>Antigens</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antivirals</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Biopsies</subject><subject>Biopsy</subject><subject>Chronic hepatitis</subject><subject>Cirrhosis</subject><subject>Departments</subject><subject>Drug use</subject><subject>Epidemiology</subject><subject>Female</subject><subject>France</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastroenterology</subject><subject>Genotype</subject><subject>Genotype &amp; phenotype</subject><subject>Hepacivirus</subject><subject>Hepatitis B</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - diagnosis</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis C</subject><subject>Hepatology</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>Hospitals, University - statistics &amp; numerical data</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferons</subject><subject>Internal medicine</subject><subject>Internal Medicine - statistics &amp; numerical data</subject><subject>Liver</subject><subject>Liver - pathology</subject><subject>Liver cancer</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Physicians</subject><subject>Prospective Studies</subject><subject>RNA</subject><subject>RNA, Viral - analysis</subject><subject>Substance Abuse, Intravenous</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0950-2688</issn><issn>1469-4409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp1kV2rEzEQhoMonlr9AYLIIujd6iSbr70RpHjOESviUfEyzGazbeo2W5Ot6L83S0vrB14F8jwzzDtDyEMKzylQ9eIj1AKY1Bo4QMW1vEVmlMu65Bzq22Q24XLiF-ReShsAqJlWd8kFFZpKKuSMtO8w4MptXRiLoSvsOg7B22Ltdjj60adiUfhQXEYX7Lpo828cJzdNsg-jiwH7Yutab31wBYY2_3bOjn7Yp6L1yWFy6T6502Gf3IPjOyefL19_WlyXy_dXbxavlqUVWo8lZ6yiTkOjgDdWNI3krGGaoq1YBzWqDljFOEVobVvXiNapRghZMdS87XQ1Jy8PfXf7Js9k86ARe7OLfovxpxnQmz9J8GuzGr6bvBVgAnKDZ8cGcfi2d2k0W5-s63sMLgcyVEkBWlVZfPKXuBn20y6SYSC4EgomiR4kG4eUoutOk1Aw0wHNPwfMNY9_j3CuOF4sC0-PAiaLfRcxWJ_OnpRM0bzIOXl08DZpHOKJV1oKXk-4PGCfRvfjhDF-NVJVShh59cHUb_nyC7u5MdfZr45ZcNtE367cOfH_0_wCGCLLvg</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>CACOUB, P.</creator><creator>GODEREL, I.</creator><creator>MORLAT, P.</creator><creator>SENE, D.</creator><creator>MYERS, R. P.</creator><creator>ALRIC, L.</creator><creator>LOUSTAUD-RATTI, V.</creator><creator>MELIN, P.</creator><creator>LIMAL, N.</creator><creator>OUZAN, D.</creator><creator>PERRONNE, C.</creator><creator>CARRAT, F.</creator><general>Cambridge University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20050401</creationdate><title>Management of chronic hepatitis C in French departments of internal medicine and infectious diseases</title><author>CACOUB, P. ; GODEREL, I. ; MORLAT, P. ; SENE, D. ; MYERS, R. P. ; ALRIC, L. ; LOUSTAUD-RATTI, V. ; MELIN, P. ; LIMAL, N. ; OUZAN, D. ; PERRONNE, C. ; CARRAT, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c588t-42231e80b704bc5bb642b281ac32f09a7f023241a0dcd99aace7b55632a84df83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Antigens</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antivirals</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Biopsies</topic><topic>Biopsy</topic><topic>Chronic hepatitis</topic><topic>Cirrhosis</topic><topic>Departments</topic><topic>Drug use</topic><topic>Epidemiology</topic><topic>Female</topic><topic>France</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastroenterology</topic><topic>Genotype</topic><topic>Genotype &amp; phenotype</topic><topic>Hepacivirus</topic><topic>Hepatitis B</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - diagnosis</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis C</topic><topic>Hepatology</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>Hospitals, University - statistics &amp; numerical data</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferons</topic><topic>Internal medicine</topic><topic>Internal Medicine - statistics &amp; numerical data</topic><topic>Liver</topic><topic>Liver - pathology</topic><topic>Liver cancer</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Physicians</topic><topic>Prospective Studies</topic><topic>RNA</topic><topic>RNA, Viral - analysis</topic><topic>Substance Abuse, Intravenous</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CACOUB, P.</creatorcontrib><creatorcontrib>GODEREL, I.</creatorcontrib><creatorcontrib>MORLAT, P.</creatorcontrib><creatorcontrib>SENE, D.</creatorcontrib><creatorcontrib>MYERS, R. P.</creatorcontrib><creatorcontrib>ALRIC, L.</creatorcontrib><creatorcontrib>LOUSTAUD-RATTI, V.</creatorcontrib><creatorcontrib>MELIN, P.</creatorcontrib><creatorcontrib>LIMAL, N.</creatorcontrib><creatorcontrib>OUZAN, D.</creatorcontrib><creatorcontrib>PERRONNE, C.</creatorcontrib><creatorcontrib>CARRAT, F.</creatorcontrib><creatorcontrib>GERMIVIC Group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Epidemiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CACOUB, P.</au><au>GODEREL, I.</au><au>MORLAT, P.</au><au>SENE, D.</au><au>MYERS, R. P.</au><au>ALRIC, L.</au><au>LOUSTAUD-RATTI, V.</au><au>MELIN, P.</au><au>LIMAL, N.</au><au>OUZAN, D.</au><au>PERRONNE, C.</au><au>CARRAT, F.</au><aucorp>GERMIVIC Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of chronic hepatitis C in French departments of internal medicine and infectious diseases</atitle><jtitle>Epidemiology and infection</jtitle><addtitle>Epidemiol. Infect</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>133</volume><issue>2</issue><spage>305</spage><epage>314</epage><pages>305-314</pages><issn>0950-2688</issn><eissn>1469-4409</eissn><coden>EPINEU</coden><abstract><![CDATA[This prospective, multicentre study was conducted during 2–30 April 2001 in the internal medicine/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic evaluation of HCV infection performed (HCV RNA, genotype, liver biopsy); determine the proportion and characteristics of patients receiving antiviral treatment; and determine if any changes in these parameters had occurred between 1995 and 2001. Patients whom had a complete pre-therapeutic evaluation (39%, 709/1834) and received antiviral treatment (38%, 690/1830) were more likely to have abnormal liver biochemistry, cirrhosis and cryoglobulinaemia (P<0·001). Injecting drug users and HIV-co-infected patients were less likely to have a complete pre-therapeutic evaluation or receive antiviral treatment (P<0·001). A complete pre-therapeutic evaluation was more often performed in 2001 than in 1995 (39% vs. 6%, P<0·001), including qualitative HCV RNA testing (91% vs. 68%, P<0·001), genotyping (59% vs. 7%, P<0·001) and a liver biopsy (60% vs. 29%, P<0·001). The frequency of anti-HCV treatment approximately doubled between 1995 and 2001 (20% vs. 38%, P<0·001). Although adherence to consensus recommendations regarding pre-therapeutic evaluation is not ideal, a substantial improvement has occurred since 1995. Nevertheless, means of increasing the availability of antiviral therapies, particularly for patients with HIV co-infection or injecting drug use, require further study.]]></abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>15816156</pmid><doi>10.1017/S0950268804003486</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-2688
ispartof Epidemiology and infection, 2005-04, Vol.133 (2), p.305-314
issn 0950-2688
1469-4409
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2870250
source Cambridge Journals Online; JSTOR Archival Journals and Primary Sources Collection; PubMed Central
subjects Adult
Antigens
Antiviral Agents - therapeutic use
Antivirals
Biochemistry
Biological and medical sciences
Biopsies
Biopsy
Chronic hepatitis
Cirrhosis
Departments
Drug use
Epidemiology
Female
France
Fundamental and applied biological sciences. Psychology
Gastroenterology
Genotype
Genotype & phenotype
Hepacivirus
Hepatitis B
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - diagnosis
Hepatitis B, Chronic - drug therapy
Hepatitis C
Hepatology
HIV
HIV Infections - drug therapy
Hospitals, University - statistics & numerical data
Human viral diseases
Humans
Infections
Infectious diseases
Interferons
Internal medicine
Internal Medicine - statistics & numerical data
Liver
Liver - pathology
Liver cancer
Male
Medical sciences
Medicine
Microbiology
Middle Aged
Patients
Physicians
Prospective Studies
RNA
RNA, Viral - analysis
Substance Abuse, Intravenous
Viral diseases
Viral hepatitis
title Management of chronic hepatitis C in French departments of internal medicine and infectious diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T23%3A01%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20chronic%20hepatitis%20C%20in%20French%20departments%20of%20internal%20medicine%20and%20infectious%20diseases&rft.jtitle=Epidemiology%20and%20infection&rft.au=CACOUB,%20P.&rft.aucorp=GERMIVIC%20Group&rft.date=2005-04-01&rft.volume=133&rft.issue=2&rft.spage=305&rft.epage=314&rft.pages=305-314&rft.issn=0950-2688&rft.eissn=1469-4409&rft.coden=EPINEU&rft_id=info:doi/10.1017/S0950268804003486&rft_dat=%3Cjstor_pubme%3E3865492%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c588t-42231e80b704bc5bb642b281ac32f09a7f023241a0dcd99aace7b55632a84df83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=205475703&rft_id=info:pmid/15816156&rft_cupid=10_1017_S0950268804003486&rft_jstor_id=3865492&rfr_iscdi=true